☆ 4.6 Review

European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer

CANCER TREATMENT REVIEWS (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.

Josep Tabernero et al.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Receipt of Targeted Therapy and Survival Outcomes in Patients With Metastatic Colorectal Cancer

Siran M. Koroukian et al.

Summary: This study aimed to identify factors associated with first-line targeted therapies among patients with metastatic colorectal cancer and investigate the association between targeted therapy and survival. The results showed that EGFR inhibitors were associated with improved survival in patients with RAS wildtype (RAS-WT) tumors, while no survival benefit was found with VEGF inhibitors in patients with RAS-WT or RAS mutant (RAS-Mut) tumors. Therefore, this study highlights the importance of using data from routine clinical care.

JAMA NETWORK OPEN (2023)

Add to Collection

Article Oncology

ANCHOR CRC: Results From a Single-Arm , Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic Colorectal Cancer

Eric Van Cutsem et al.

Summary: This study aimed to evaluate the efficacy, safety, and quality of life of the combination of encorafenib + binimetinib + cetuximab as first-line treatment for BRAF(V600E)-mutated mCRC. The results showed that this combination therapy was effective with a manageable safety profile.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Meeting Abstract Oncology

BREAKWATER safety lead-in (SLI): Encorafenib plus cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC)

Scott Kopetz et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

WJOG13219G: Triplet versus doublet in patients with previously untreated BRAFV600E-mutant metastatic colorectal cancer: A multi-institutional real-world data analysis (BRACELET study)

Keitaro Shimozaki et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAF(V600E) metastatic colorectal cancer

Van K. Morris et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Heinz-Josef Lenz et al.

Summary: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019

Jonathan M. Kocarnik et al.

Summary: The global burden of cancer is substantial and growing, with differences in burden based on Sociodemographic Index (SDI). The largest percentage increase in the numbers of cases and deaths occurred in the low and low-middle SDI quintiles from 2010 to 2019.

JAMA ONCOLOGY (2022)

Add to Collection

Article Oncology

European cancer mortality predictions for the year 2022 with focus on ovarian cancer

M. Dalmartello et al.

Summary: Cancer mortality rates in Europe have been decreasing over the last three decades. Lung cancer and ovarian cancer rates have decreased, while stomach cancer, colorectal cancer, breast cancer, and prostate cancer rates have shown significant declines. Leukemia and uterine cancer mortality rates have also decreased.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?

Roberto Moretto et al.

Summary: Recent data suggest that BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients with right-sided tumors may benefit from the triplet regimen, while those with left-sided tumors may have a detrimental effect. Differences in tumor biology between right- and left-sided BRAFV600E-mutated CRCs were observed. The use of FOLFOXIRI +/- bevacizumab is supported only in BRAFV600E-mutated mCRC patients with right-sided tumors.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Clinical management of metastatic colorectal cancer in the era of precision medicine

Fortunato Ciardiello et al.

Summary: This review summarizes the progress in the clinical management of patients with metastatic colorectal cancer (mCRC) in the era of precision medicine. Molecular stratification, based on the current treatment algorithm, has been a significant step towards implementing more effective therapeutic approaches. Integrating tumor gene alterations with tumor and microenvironment gene and protein expression profiling, host immune competence, and applying dynamic changes to precision medicine-based continuum of care, could lead to the identification of individual prognostic and predictive parameters for choosing the most appropriate therapeutic program for each patient.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Review Oncology

BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications

Valentina Angerilli et al.

Summary: Molecular biology has greatly increased our understanding of the heterogeneous molecular landscape of colorectal cancer (CRC), with up to 15% of CRC patients harboring the BRAF p.V600E somatic mutation (BRAFmt), a negative prognostic marker in patients with metastatic CRC (mCRC). BRAF mutational testing is now recommended in mCRC patients, but efforts are needed to further stratify patients carrying this mutation.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

Add to Collection

Review Oncology

Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer

Maria Grazia Rodriquenz et al.

Summary: Approximately 8-15% of patients with metastatic colorectal cancer (mCRC) have mutation in the BRAF gene. Recent advances in molecular biology have improved our understanding of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including the high rate of overlapping with MSI-H status and the presence of non-V600E mutations associated with better behavior. Treatment options for this subgroup have expanded, but the development of secondary resistance remains a major challenge.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

Add to Collection

Review Oncology

Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAFV600E-mutant metastatic and/or unresectable colorectal cancer

Pilar Garcia-Alfonso et al.

Summary: Approximately 8-10% of metastatic colorectal cancer tumors have BRAF(V600E) mutations. Single-agent BRAF inhibitors have minimal efficacy, while combining BRAF inhibitors with anti-EGFR therapy improves outcomes. Patients with BRAF(V600E)-mutant mCRC have worse outcomes compared to those with BRAF wild-type mCRC.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

Add to Collection

Article Oncology

Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial

Zhan Wang et al.

Summary: This study evaluated the safety and efficacy of a new protocol using vemurafenib and cetuximab combined with FOLFIRI in patients with BRAF V600E-mutated colorectal cancer. The results showed promising antitumour activity and tolerable toxicity with this combination therapy.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

Luis A. Diaz et al.

Summary: The final overall survival analysis of the KEYNOTE-177 study showed that while pembrolizumab continued to demonstrate durable antitumor activity and fewer treatment-related adverse events compared to chemotherapy in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, there was no statistically significant difference in overall survival between the two treatment groups.

LANCET ONCOLOGY (2022)

Add to Collection

Article Oncology

Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer

M. Benavides et al.

Summary: Liquid biopsy is an effective and faster method for identifying guideline-recommended biomarkers in patients with mCRC compared to standard tissue testing. Adding ctDNA genotyping to clinical practice has the potential to improve care for mCRC patients.

ESMO OPEN (2022)

Add to Collection

Article Oncology

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

T. Andre et al.

Summary: This study confirms the long-term benefit of nivolumab plus low-dose ipilimumab for previously treated patients with MSI-H/dMMR mCRC, with a manageable safety profile.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC).

Scott Kopetz et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Real-world first-line treatment of patients with BRAFV600E???????- mutant metastatic colorectal cancer: the CAPSTAN CRC study

E. Martinelli et al.

Summary: This study is the largest real-world analysis to date of patients with BRAF(V600E) mutant mCRC, providing valuable insights into routine first-line treatment practices for these patients. The results highlight the intrinsic aggressiveness of this disease subgroup and emphasize the urgent need for more effective treatment options in this setting.

ESMO OPEN (2022)

Add to Collection

Meeting Abstract Oncology

BREAKWATER safety lead-in (SLI): Encorafenib (E) plus cetuximab (C) plus chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC)

J. Tabernero et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

Elena Elez et al.

Summary: In colorectal cancer patients, inactivating mutations in the RNF43 gene are associated with patients' response rates and survival outcomes to anti-BRAF/EGFR therapy. This suggests that the status of the RNF43 gene may serve as a predictive biomarker for patients' clinical outcomes.

NATURE MEDICINE (2022)

Add to Collection

Review Gastroenterology & Hepatology

Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer

Javierd Ros et al.

Summary: BRAF-V600E mCRC is a challenging disease, with poor response to standard chemotherapy. However, combining the BRAF inhibitor encorafenib with the anti-epidermal growth factor receptor cetuximab has shown promising results. The BEACON trial has been a significant therapeutic change in this field, and there is ongoing research on biomarkers and novel combinations including BRAF inhibitors with immune checkpoint inhibitors.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study

S. Kopetz et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer

Thiru Prasanna et al.

Summary: The study indicates that there is no significant difference in survival rates between BRAF MT and WT after metastasectomy in mCRC, but the survival rate is significantly better in BRAF MT patients after metastasectomy. The survival after metastasectomy in BRAF MT patients may be influenced by MMR status.

CURRENT PROBLEMS IN CANCER (2021)

Add to Collection

Review Oncology

BRAF Mutations as Actionable Targets: A Paradigm Shift in the Management of Colorectal Cancer and Novel Avenues

Ibrahim Halil Sahin et al.

Summary: BRAFV600E mutation is the most common oncogenic alteration in colorectal cancer, recent studies have found a combination therapy of BRAF and/or MEK inhibition with epidermal growth factor receptor-directed therapy to be effective for patients with BRAFV600-mutant colorectal cancer. Immune checkpoint inhibitor therapy is more appealing for patients with BRAFV600E-mutant mismatch repair-deficient colorectal cancer.

JCO ONCOLOGY PRACTICE (2021)

Add to Collection

Article Oncology

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

Scott Kopetz et al.

Summary: Combination therapy of vemurafenib and irinotecan in patients with BRAF(V600E)-mutated colorectal cancer has shown improved progression-free survival, response rate, and disease control rate, as well as reduced BRAF(V600E) variant allele frequency in circulating tumor DNA.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers

Tadeusz Dyba et al.

Summary: This article presents the incidence and mortality estimates for 25 major cancers across 40 individual countries within European areas and the EU-27 for the year 2020. The most common cancers are breast, colorectal, lung, and prostate cancers, which account for half the overall cancer burden in Europe. The estimates provide a basis for setting priorities in cancer-control measures across Europe.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Josep Tabernero et al.

Summary: The study evaluated different treatment regimens for patients with BRAF V600E-mutant metastatic colorectal cancer, showing that encorafenib plus cetuximab improved overall survival, objective response rate, and progression-free survival compared to standard chemotherapy.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Diagnostic value of diffusion-weighted imaging/magnetic resonance imaging for peritoneal metastasis from malignant tumor A systematic review and meta-analysis

Li Dong et al.

Summary: The study found that DWI magnetic resonance imaging is highly sensitive and specific for detecting peritoneal metastases from various abdominal cancers.

MEDICINE (2021)

Add to Collection

Review Oncology

Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines

A. Grothey et al.

Summary: Colorectal cancer remains a leading cause of cancer-related deaths globally, with the mutation in the BRAF gene, particularly the V600E substitution, affecting 10% of metastatic CRC patients and indicating a poor prognosis. Recent advancements in combination therapies targeting the MAPK pathway have shown promising results in treating BRAF V600E-mutated mCRC patients, offering new hope in the management of this subtype of cancer.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Review Surgery

Therapeutic implications of B-RAF mutations in colorectal cancer

H. Lebrun et al.

Summary: CRC patients with B-RAF mutation have a poor prognosis. The efficacy of first-line chemotherapy with anti-VEGF for metastatic CRC is being questioned, while the effectiveness of anti-EGFR remains uncertain. Immunotherapy shows promising results in patients with microsatellite instability.

JOURNAL OF VISCERAL SURGERY (2021)

Add to Collection

Meeting Abstract Oncology

ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer

E. Van Cutsem et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR plus /- MEK inhibitors

E. Elez et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study

Roberto Moretto et al.

Summary: The TRIBE2 study did not find specific gene expression signatures that could identify BRAF-mutant mCRC patients who may benefit more from upfront FOLFOXIRI/bevacizumab. However, it did show that patients with ECOG-PS >0 and left-sided tumors may not benefit from intensified treatment.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Meeting Abstract Oncology

Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).

Sebastian Stintzing et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

BREAKWATER: Randomized phase 3 study of encorafenib (enco) plus cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).

Scott Kopetz et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer A systematic review and meta-analysis

Hailing Zhang et al.

Summary: Combining bevacizumab with the FOLFOX regimen is more effective than FOLFOX alone in the treatment of advanced colorectal cancer, but may also increase the risk of gastrointestinal adverse reactions.

MEDICINE (2021)

Add to Collection

Review Pathology

BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options

Michael Hummel et al.

Summary: In the past 25 years, treatment of metastatic colorectal cancer has undergone profound changes, with the introduction of newer chemotherapeutics and targeted therapies leading to more personalized treatment strategies.

PATHOLOGE (2021)

Add to Collection

Article Oncology

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164

Dung T. Le et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Review Oncology

The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer

Giuseppe Nicolo Fanelli et al.

CANCER CELL INTERNATIONAL (2020)

Add to Collection

Article Oncology

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

Gary Middleton et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis

Fabio Gelsomino et al.

CANCERS (2020)

Add to Collection

Meeting Abstract Oncology

Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients

R. Corcoran et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Review Oncology

ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper

Arvind Dasari et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer

Chiara Cremolini et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Review Oncology

Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer

Benny Johnson et al.

TARGETED ONCOLOGY (2020)

Add to Collection

Article Oncology

Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial

Elisabetta Petracci et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)

Add to Collection

Review Oncology

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

F. Mosele et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Oncology

Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline

E. Gabriela Chiorean et al.

JCO GLOBAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization

Marta Schirripa et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Oncology

A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study

Fotios Loupakis et al.

EUROPEAN JOURNAL OF CANCER (2019)

Add to Collection

Review Biochemistry & Molecular Biology

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights

Francesco Caputo et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Add to Collection

Article Oncology

Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience

Pietro Paolo Vitiello et al.

CANCERS (2019)

Add to Collection

Article Oncology

Clinicopathological Significance of BRAFV600E Mutation in Colorectal Cancer: An Updated Meta-Analysis

Jianhua Wang et al.

JOURNAL OF CANCER (2019)

Add to Collection

Article Gastroenterology & Hepatology

Predictive and Prognostic Implications of Mutation Profiling and Microsatellite Instability Status in Patients with Metastatic Colorectal Carcinoma

Jianhua Liu et al.

GASTROENTEROLOGY RESEARCH AND PRACTICE (2018)

Add to Collection

Article Oncology

Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer

Ryan B. Corcoran et al.

CANCER DISCOVERY (2018)

Add to Collection

Article Surgery

Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer

Georgios Antonios Margonis et al.

JAMA SURGERY (2018)

Add to Collection

Article Oncology

BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression

David Barras et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Oncology

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

S. Stintzing et al.

EUROPEAN JOURNAL OF CANCER (2017)

Add to Collection

Article Oncology

Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer

Jeremy C. Jones et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Michael J. Overman et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Oncology

535PENCORAFENIB (LGX818), AN ORAL BRAF INHIBITOR, IN PATIENTS (PTS) WITH BRAF V600E METASTATIC COLORECTAL CANCER (MCRC): RESULTS OF DOSE EXPANSION IN AN OPEN-LABEL, PHASE 1 STUDY

C.A. Gomez-Roca et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Review Oncology

Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches

John H. Strickler et al.

CANCER TREATMENT REVIEWS (2017)

Add to Collection

Article Gastroenterology & Hepatology

Pattern and Dynamics of Distant Metastases in Metastatic Colorectal Cancer

Julian Walter Holch et al.

VISCERAL MEDICINE (2017)

Add to Collection

Article Oncology

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

E. Van Cutsem et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection

Review Oncology

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis

Filippo Pietrantonio et al.

EUROPEAN JOURNAL OF CANCER (2015)

Add to Collection

Article Oncology

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

Scott Kopetz et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Article Oncology

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer

Ryan B. Corcoran et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Article Biochemistry & Molecular Biology

The consensus molecular subtypes of colorectal cancer

Justin Guinney et al.

NATURE MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

Gerald S. Falchook et al.

LANCET (2012)

Add to Collection

Article Oncology

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

Ryan B. Corcoran et al.

CANCER DISCOVERY (2012)

Add to Collection

Article Oncology

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

C. Bokemeyer et al.

ANNALS OF ONCOLOGY (2011)

Add to Collection

Article Oncology

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

Eric Van Cutsem et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Review Oncology

CT, MRI and PET imaging in peritoneal malignancy

Chirag M. Patel et al.

CANCER IMAGING (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.